SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) Delayed: 231.29 +2.90 (1.27%)
Previous Close $228.39    52 Week High $126.07 
Open $228.95    52 Week Low $94.28 
Day High $231.45    P/E 48.09 
Day Low $227.50    EPS $4.81 
Volume 8,518,208